Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ORMP 
Oramed Pharmaceuticals Inc (ORMP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/03/2025: ORMP (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $3.25
1 Year Target Price $3.25
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 15.32% | Avg. Invested days 41 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 07/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 89.05M USD | Price to earnings Ratio - | 1Y Target Price 3.25 |
Price to earnings Ratio - | 1Y Target Price 3.25 | ||
Volume (30-day avg) 1 | Beta 1.62 | 52 Weeks Range 1.82 - 3.09 | Updated Date 07/4/2025 |
52 Weeks Range 1.82 - 3.09 | Updated Date 07/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.71 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -225% |
Management Effectiveness
Return on Assets (TTM) -5.1% | Return on Equity (TTM) -18.51% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -41289009 | Price to Sales(TTM) 44.53 |
Enterprise Value -41289009 | Price to Sales(TTM) 44.53 | ||
Enterprise Value to Revenue 2.86 | Enterprise Value to EBITDA 0.52 | Shares Outstanding 40850500 | Shares Floating 32050041 |
Shares Outstanding 40850500 | Shares Floating 32050041 | ||
Percent Insiders 13.58 | Percent Institutions 19.11 |
Upturn AI SWOT
Oramed Pharmaceuticals Inc
Company Overview
History and Background
Oramed Pharmaceuticals Inc. was founded in 2002. It focuses on the development of oral drug delivery systems, primarily for diabetes. Its major milestone is the development of oral insulin capsules, seeking to transform diabetes treatment.
Core Business Areas
- Oral Insulin: Development and commercialization of oral insulin capsules (ORMD-0801) for the treatment of diabetes.
- Oral GLP-1: Development of oral GLP-1 (ORMD-0804) for treating Type 2 diabetes and other indications.
Leadership and Structure
Nadav Kidron is the CEO. The company has a board of directors and operates with research and development, clinical trial, and administrative departments.
Top Products and Market Share
Key Offerings
- ORMD-0801 (Oral Insulin Capsule): Oramed's lead product is an oral insulin capsule aimed at replacing insulin injections for Type 2 diabetes patients. It's currently in Phase 3 clinical trials. Market share is currently 0, as the product isn't yet on the market, but potential is huge if proven successful. Competitors include Novo Nordisk (NVO) and Eli Lilly (LLY) who offer injectable insulin products. The market addressable to Oramed would be a sub-section of the Type 2 diabetes patients using insulin.
- ORMD-0804 (Oral GLP-1): An oral glucagon-like peptide-1 (GLP-1) receptor agonist being developed for Type 2 diabetes and other indications. This is currently in Phase 1 trials. Market share is currently 0, as the product isn't yet on the market, but it has great potential if proven successful. Competitors include Novo Nordisk (NVO) and Eli Lilly (LLY) who offer injectable and oral GLP-1 products.
Market Dynamics
Industry Overview
The pharmaceutical industry for diabetes treatments is highly competitive and regulated. There's a growing demand for more convenient and less invasive treatments like oral medications.
Positioning
Oramed is positioning itself as an innovator in oral drug delivery for diabetes, offering a potentially more convenient alternative to injections. It's a small company competing with larger, established pharmaceutical giants.
Total Addressable Market (TAM)
The global diabetes drug market is estimated to be over $100 billion. The oral insulin market, if Oramed's product is approved, could capture a significant portion of the injectable insulin market. It is well positioned due to ease of use.
Upturn SWOT Analysis
Strengths
- Innovative oral drug delivery technology
- Potential to disrupt the diabetes treatment market
- Experienced management team in oral drug delivery
Weaknesses
- Reliance on successful clinical trials
- Limited financial resources compared to larger pharmaceutical companies
- Product not yet approved by regulatory agencies
- High cash burn rate
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion to other therapeutic areas beyond diabetes
- Increasing global prevalence of diabetes
- Growing interest in convenient oral therapies.
Threats
- Failure to achieve positive clinical trial results
- Regulatory hurdles and approval delays
- Competition from existing and new diabetes treatments
- Patent disputes
Competitors and Market Share
Key Competitors
- NVO
- LLY
- SNY
Competitive Landscape
Oramed faces intense competition from established pharmaceutical companies with greater resources and approved diabetes treatments. Its competitive advantage lies in its oral drug delivery technology, offering a more convenient alternative to injections. However, it must demonstrate clinical efficacy and safety to compete effectively.
Growth Trajectory and Initiatives
Historical Growth: Oramed's historical growth has been driven by progressing its oral insulin and oral GLP-1 programs through clinical trials. No sales have occurred yet.
Future Projections: Future growth depends on successful clinical trial outcomes, regulatory approvals, and commercialization efforts. Analyst estimates vary widely, with significant potential upside if ORMD-0801 is approved.
Recent Initiatives: Focus is on completing Phase 3 trials for ORMD-0801 and advancing ORMD-0804 to Phase 2.
Summary
Oramed Pharmaceuticals is a high-risk, high-reward company focused on revolutionizing diabetes treatment through oral insulin. Success hinges on positive clinical trial results and regulatory approval. While its innovative technology presents a significant opportunity, the company faces intense competition and financial challenges. The ability to secure partnerships and effectively commercialize products is crucial for future success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Oramed Pharmaceuticals Inc. SEC Filings, Investor Presentations, Company Website, Financial News Outlets
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on individual research and consultation with a qualified financial advisor. Market share estimates are approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Oramed Pharmaceuticals Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2006-04-21 | President, CEO & Executive Chairman Mr. Nadav Kidron Esq. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://www.oramed.com |
Full time employees - | Website https://www.oramed.com | ||
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.